CHRISTOPHER F NICODEMUS, M.D.
Osteopathic Medicine in Wellesley, MA

2011025, Oct 20, 2011

Oct 7, 2010

12/900251

Birgit C. Schultes - Arlington MA, US
Christopher F. Nicodemus - Charlestown MA, US

A61K 39/395, A61P 35/00, A61P 37/06, A61P 37/04

4241331, 4241301, 4241411, 4241551, 4241421

The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.

2013005, Mar 7, 2013

Apr 26, 2012

13/456492

Birgit C. Schultes - Arlington MA, US
Christopher F. Nicodemus - Charlestown MA, US

A61K 39/395, A61P 35/00, A61P 37/02, A61P 37/08

4241331, 4241301, 4241411, 4241421

The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.

2008031, Dec 18, 2008

Oct 31, 2007

11/981713

Birgit C. Schultes - Arlington MA, US
Christopher F. Nicodemus - Charlestown MA, US
Antoine A. Noujaim - Edmonton, CA
Ragupathy Madiyalakan - Edmonton, CA

AltaRex Medical Corp. - Edmonton

A61K 39/395, A61P 35/00

4241551

Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.

2011009, Apr 21, 2011

Oct 7, 2010

12/900256

MANUEL L. PENICHET - LOS ANGELES CA, US
BIRGIT C. SCHULTES - ARLINGTON MA, US
CHRISTOPHER F. NICODEMUS - CHARLESTOWN MA, US
TRACY R. DANIELS - WOODLAND HILLS CA, US
GUSTAVO HELGUERA - LONG BEACH CA, US
JOSE A. RODRIGUEZ - PARAMOUNT CA, US

A61K 39/395, A61P 35/00, C07K 16/18

4241391, 4241551, 4241561, 5303873, 5303879, 53038815, 5303888

The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).

2013002, Jan 24, 2013

Feb 14, 2012

13/372557

MANUEL L. PENICHET - LOS ANGELES CA, US
BIRGIT C. SCHULTES - ARLINGTON MA, US
CHRISTOPHER F. NICODEMUS - CHARLESTOWN MA, US
TRACY R. DANIELS - WOODLAND HILLS CA, US
GUSTAVO HELGUERA - LONG BEACH CA, US
JOSE A. RODRIGUEZ - PARAMOUNT CA, US

C07K 16/18, C07K 19/00, A61P 37/04, A61K 39/395

4241561, 5303888, 5303873, 53038815, 53038885, 5303879, 4241551, 5303911

The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).

8038994, Oct 18, 2011

Apr 26, 2004

10/831886

Birgit C. Schultes - Arlington MA, US
Christopher F. Nicodemus - Charlestown MA, US
Antoine A. Noujaim - Edmonton, CA
Ragupathy Madiyalakan - Edmonton, CA

Quest Pharmatech Inc.

A61K 39/395

4241381, 4241411, 4241561

Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.

2005003, Feb 10, 2005

Mar 8, 2002

10/472167

Christopher Nicodemus - Charlestown MA, US
Birgit Schultes - Arlington MA, US

A61K039/395

424155100

The invention is therapeutic methods and compositions that alter the immunogenicity of the host.